Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

790
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
790
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

588
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

536
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
536
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

691
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
691
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

620
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

3.9K
The pathophysiology of pneumonia involves the following steps:
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same author

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same author

Multi-organ metabolic connectivity mapping in advanced pulmonary arterial hypertension: a group-level 18 F-FDG PET-controlled study.

BMC medical imaging·2026
Same author

Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS.

ERJ open research·2026
Same author

The challenging combination of a high cardiac output and pulmonary arterial hypertension.

The European respiratory journal·2026
Same author

Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.

ERJ open research·2026

Related Experiment Video

Updated: Mar 18, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Interferon-induced pulmonary hypertension: an update.

Laurent Savale1, Marie-Camille Chaumais, Caroline O'Connell

  • 1aUniversity Paris-Sud, Faculté de Médecine, Université Paris-Saclay bAP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre cINSERM UMR_S 999, Hôpital Marie Lannelongue dFaculté de Pharmacie, University Paris-Sud eAP-HP, Service de Pharmacie, DHU Thorax Innovation, Hôpital Antoine Béclère, Paris, France.

Current Opinion in Pulmonary Medicine
|July 9, 2016
PubMed
Summary

Interferon therapies, though rare, can cause life-threatening pulmonary arterial hypertension (PAH). Clinical and experimental evidence suggests a causal link between interferon exposure and PAH development.

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

26.2K

Related Experiment Videos

Last Updated: Mar 18, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.1K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

26.2K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Toxicology

Background:

  • Pulmonary adverse effects from interferon (IFN) therapies are uncommon but potentially fatal.
  • Interferon is increasingly recognized as a risk factor for pulmonary arterial hypertension (PAH).

Purpose of the Study:

  • To review clinical and experimental data on the association between interferon exposure and PAH.
  • To evaluate the evidence supporting a causal relationship between IFNs and PAH.

Main Methods:

  • Review of clinical case reports and experimental studies.
  • Analysis of data from patients exposed to interferon-α or interferon-β.
  • Examination of basic science research on interferon's role in pulmonary hypertension.

Main Results:

  • Multiple cases suggest a link between IFN-α/IFN-β exposure and PAH.
  • Reversibility of PAH after IFN cessation observed in some patients.
  • Interferon may act as an additional trigger for PAH in patients with co-existing risk factors.

Conclusions:

  • Clinical and experimental data strongly support a link between interferon exposure and the risk of developing PAH.
  • Further research is needed to fully elucidate the mechanisms and confirm causality, especially in complex patient populations.